IBI355 + IBI355 placebo
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Sjögren's Syndrome
Conditions
Primary Sjögren's Syndrome
Trial Timeline
Jul 14, 2024 → Jul 25, 2025
NCT ID
NCT06484855About IBI355 + IBI355 placebo
IBI355 + IBI355 placebo is a phase 1 stage product being developed by Innovent Biologics for Primary Sjögren's Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT06484855. Target conditions include Primary Sjögren's Syndrome.
What happened to similar drugs?
20 of 20 similar drugs in Primary Sjögren's Syndrome were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06484855 | Phase 1 | Completed |
Competing Products
20 competing products in Primary Sjögren's Syndrome